Mass General Brigham
Health Plan

Rezdiffra (resmetiron)
Effective 07/01/2026

Plan	☐ MassHealth UPPL ☒ Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit		
Specialty Limitations	N/A		
Contact Information	**Medical Benefit** **Pharmacy Benefit**	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview
Rezdiffra (resmetiron) is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Rezdiffra should be avoided in patients with decompensated cirrhosis.

Coverage Guidelines
If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs
OR
Submission of MEDICAL records (e.g., chart notes) documenting ALL of the following:

1. Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH)
2. Member does not have cirrhosis (e.g., decompensated cirrhosis)
3. Member is 18 years of age or older
4. Disease is fibrosis stage F2 or F3 as confirmed by one of the following:
    a. Both of the following:
        i. Fibrosis 4 index (FIB-4) score greater than or equal to 1.3
        ii. One of the following:
            1. Enhanced liver fibrosis (ELF) test
            2. Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) (e.g., FibroScan)
    b. One of the following:
        i. FibroScan aspartate aminotransferase (FAST)
        ii. MRI aspartate aminotransferase (MAST)
        iii. Magnetic Resonance Elastography combined with fibrosis-4 index (MEFIB)
        iv. Liver biopsy within the past 12 months
5. Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)

6. Member has presence of at least one metabolic risk factor (e.g., type 2 diabetes, hypertension, obesity, reduced HDL cholesterol, raised cholesterol)
7. Prescribed by or in consultation with one of the following:
    a. Gastroenterologist
    b. Hepatologist
    c. Endocrinologist
8. Member has been counseled on limiting alcohol consumption
9. Requested medication will not be used in combination with Wegovy (semaglutide) for the treatment of MASH

Continuation of Therapy

Submission of MEDICAL RECORDS (e.g., chart notes) documenting ALL of the following:

1. Positive clinical response to therapy, or ongoing stability (e.g., improvement in liver function tests (LFTs), fibrosis stage improvement, improvement from baseline on MASH-specific imaging [VCTE >/= 25%, MRE >/= 20%, etc.], etc.)
2. Requested medication will continue to be used as an adjunct to lifestyle modification (e.g. dietary or caloric restriction, exercise, behavioral support, community-based program)
3. Member has not progressed to cirrhosis
4. Requested medication is not being co-administered with Wegovy (semaglutide) for the treatment of MASH
5. Prescribed by or in consultation with one of the following:
    a. Gastroenterologist
    b. Hepatologist
    c. Endocrinologist

Limitations

1. Initial and reauthorization approval will be granted for 12 months.
2. The following quantity limitations apply:

Drug Name and Dosage Form	Quantity Limit
Rezdiffra tablet	1 tablet per day

References

1. American Association for the Study of Liver Diseases (AASLD). New MASLD nomenclature. AASLD Web site. June 2023. https://www.aasld.org/new-masld-nomenclature. Accessed March 15, 2024.
2. American Diabetes Association Professional Practice Committee. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes – 2024. *Diabetes Care*. 2024;47(Suppl 1):S1-S321. doi: 10.2337/dc24.
3. Andersson A, Kelly M, Imajo K, et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. *Clin Gastroenterol Hepatol*. 2022;20(11):2451-2461.e3. doi: 10.1016/j.cgh.2021.09.041.
4. Bernstein D, Kovalic AJ. Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease (NAFLD). *Metabol Open*. 2022;13:100158. doi: 0.1016/j.metop.2021.100158.

5. Cao YT, Xiang LL, Qi F, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. *EClinicalMedicine*. 2022;51:101547. Doi:10.1016/j.eclinm.2022.101547.
6. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
7. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. *J Hepatol*. 2021;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025.
8. EASL; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388-1402.
9. Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med*. 2024[a];390:497-509. doi: 10.1056/NEJMoa2309000.
10. Harrison SA, Ratzui V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2024[b];59(1):51-63. doi: 10.1111/apt.17734.
11. Harrison SA, Taub, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. *Nat Med*. 2023;29(1):2919-2928. doi: 10.1038/s41591-023-02603-1.
12. Hatziagelaki E, Paschou SA, Schon M, et al. NAFLD and thyroid function: pathophysiologic and therapeutic considerations. *Trends Endocrinol Metab*. 2022;33(11):755-768. doi: 10.1016/j.tem.2022.08.001.
13. Institute for Clinical and Economic Review (ICER). Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH) (final evidence report). May 25, 2023. https://icer.org/wp-content/uploads/2022/10/NASH-Final-Report_For-Publication_053023.pdf. Accessed March 15, 2024.
14. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2021;161:1657-1669. doi: 10.1053/j/gastro.2021.07.049.
15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41(6):1313-1321. doi: 10.1002/hep.20701.
16. Lim JK, Flamm SL, Singh S, et al. American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis. *Gastroenterology*. 2017;152(6):1536-1543. doi: 10.1053/j.gastro.2017.03.017.
17. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. *Gastroenterology*. 2022;163(3):764-774.e1. doi: 10.1053/j/gastro.2022.06.023.
18. Loomba R, Lim JK, Patton H, El-Serag HB. AGA Clinical Practice Update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2020;158(6):1822-1830. doi: 10.1053/j/gastro.2019.12.053.
19. Madrigal Pharmaceuticals. The resmetirom clinical development program: leading the way in NASH research. Madrigal Pharmaceuticals Web site. 2024. https://www.madrigalpharma.com/our-programs/resmetirom/. Accessed March 15, 2024.

20. Mostafa M, Abdelkader A, Evans JJ, Hagen CE, Hartley CP. Fatty liver disease: a practical approach. *Arch Pathol Lab Med*. 2020;144:62-70.
21. Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. *Intern Emerg Med*. 2023;18(4):993-1006. doi: 10.1007/s11739-023-03203-0.
22. Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. *Clin Liv Dis (Hoboken)*. 2012;1(4):99-103. doi: 10.1002/cld.81.
23. Rezdiffra (resmetirom) [prescribing information]. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc.; March 2024.
24. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023(a);77(5):1797-1835. doi: 10.1097/HEP.0000000000000323.
25. Rinella ME, Lazarus JV, Ratziu V, et al for the NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *J Hepatol*. 2023(b);79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003.
26. Sangro P, de la Torre Alaez M, Sangro B, D'Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacologic treatment. *J Physiol Biochem*. 2023;79(4);869-879. doi: 10.1007/s13105-023-00954-4.
27. Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. *J Hepatol*. 2023;79(2):552-566. doi: 10.1016/j.jhep.2023.03.038.
28. Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA Clinical Practice Update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2023;165(4):1080-1088. doi: 10.1053/j/gastro.2023.06.013.
29. Younossi AZ, Corey KE, Lim JK. AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. *Gastroenterology*. 2021;160:912-918. doi: 10.1053/j/gastro.2020.11.051.

Review History

10/09/2024 – Reviewed at October P&T. Effective 01/01/2025.
04/15/2026 – Reviewed and updated at April P&T. Updating initial and reauthorization criteria to require submission of medical records. In initial and reauthorization criteria member must not have cirrhosis. Initial criteria being updated to define diagnostic parameters for F2 or F3 fibrosis. Use as adjunct to lifestyle modifications being added to initial and reauthorization criteria. Endocrinologist is being added as an approvable prescribing or consulting specialist and specialist prescribing/consulting requirements are being added to the reauthorization criteria. Adding requirement that member is counseled on limiting alcohol consumption to the initial criteria and specifying that Rezdiffra will not be used in combination with Wegovy for the treatment of MASH. Updating reauthorization criteria to define the clinical response to therapy. Effective 07/01/2026.